Eflornithine is under clinical development by Panbela Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Eflornithine’s likelihood of approval (LoA) and phase transition for Gastric Cancer took place on 22 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Eflornithine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Eflornithine overview

Eflornithine hydrochloride (CPP-1X) is under development for the treatment of non-small cell lung cancer, refractory or relapsed neuroblastoma, gastric cancer, pancreatic cancer and early onset type 1 diabetes mellitus. The drug candidate is administered through oral route in the form of tablet. CPP-1X acts by targeting ornithine decarboxylase. CPP-1X is a difluoromethylated ornithine (DFMO) compound that displays antiapoptotic, antiangiogenic and antiparasitic activity. It was also under development for the treatment of familial adenomatous polyposis.

Panbela Therapeutics overview

Panbela Therapeutics (Panbela), formerly Sun BioPharma Inc is a biopharmaceutical company. It develops disruptive therapeutics for the treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101. Its SBP-101 produces superior anti-tumour activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma, and pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, cancer centres universities, and research centres for the development of drugs. Panbela is headquartered in Waconia, Minnesota, the US.

Quick View Eflornithine LOA Data

Report Segments
  • Innovator
Drug Name
  • Eflornithine
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.